Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1977 Jun;59(6):1017–1026. doi: 10.1172/JCI108724

Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.

M S Mitchell, M B Mokyr, J M Davis
PMCID: PMC372313  PMID: 863999

Abstract

The effects of chemotherapy, with nitrosoureas or dimethyl-triazeno-imidazole-carboxamide (DTIC), or immunotherapy with Bacillus Calmette-Guérin (BCG), on cell-mediated immunity (CMI), and serum blocking factor (BF) to melanoma cells were studied in 23 patients. Studies were performed with autologous or allogenic melanoma target cells obtained from recent biopsy, in 16 mm diameter plastic wells. Assays for lymphocyte-mediated cytotoxicity and BF were performed at weekly intervals over the course of 3-4 mo, with some studies extending beyond 3 yr. The specificity of cytotoxicity was good with these methods. Nine patients given nitrosoureas, predominantly methyl-chloroethyl-cyclohexyl-nitrosourea, showed a transient decline in CMI from 42.2 to 14% 3 wk after administration of a single dose of the agent, with a rapid recovery within 1 week. 10 patients given 5-day courses of DTIC at 3-wk intervals showed no decline in CMI after two courses, and 7 of the 10 had no decline even after three courses. Three of the four patients who achieved a remission lost BF previously present: BF reappeared in both patients studied during a subsequent relapse. BCG intradermally or intralesionally elevated CMI within 2 mo after initiation of therapy, but despite continuation of the injections CMI returned to base line in all but two of the nine patients studied. These results indicate that chemotherapy for melanoma with nitrosoureas or DTIC at these schedules is not profoundly immunosuppressive towards tumor-specific immunity, as measured by our procedures. Putative immunotherapy with BCG at these schedules was likewise only transiently stimulatory.

Full text

PDF
1017

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baldwin R. W., Price M. R., Robins R. A. Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol. 1972 Aug 9;238(84):185–186. doi: 10.1038/newbio238185a0. [DOI] [PubMed] [Google Scholar]
  2. Baldwin R. W., Price M. R., Robins R. A. Inhibition of hepatoma-immune lymph-node cell cytotoxicity by tumour-bearer serum, and solubilized hepatoma antigen. Int J Cancer. 1973 May;11(3):527–535. doi: 10.1002/ijc.2910110304. [DOI] [PubMed] [Google Scholar]
  3. Bruckner H. W., Mokyr M. B., Mitchell M. S. Effect of imidazole-4-carboxamide, 5-(3,3-dimethyl-1-triazeno) on immunity in patients with malignant melanoma. Cancer Res. 1974 Jan;34(1):181–183. [PubMed] [Google Scholar]
  4. Dlugi A. M., Robie K. M., Mitchell M. S. Failure of bleomycin to affect humoral or cell-mediated immunity in the mouse. Cancer Res. 1974 Oct;34(10):2504–2507. [PubMed] [Google Scholar]
  5. HUMPHREYS S. R., CHIRIGOS M. A., MILSTEAD K. L., MANTEL N., GOLDIN A. Studies on the suppression of the homograft response with folic acid antagonists. J Natl Cancer Inst. 1961 Aug;27:259–276. [PubMed] [Google Scholar]
  6. Hellström I., Hellström K. E., Sjögren H. O., Warner G. A. Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer. 1971 Jan 15;7(1):1–16. doi: 10.1002/ijc.2910070102. [DOI] [PubMed] [Google Scholar]
  7. Hellström I., Hellström K. E. Some recent studies on cellular immunity to human melanomas. Fed Proc. 1973 Feb;32(2):156–159. [PubMed] [Google Scholar]
  8. Hellström K. E., Hellström I. Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol. 1974;18:209–277. doi: 10.1016/s0065-2776(08)60311-9. [DOI] [PubMed] [Google Scholar]
  9. Heppner G. H., Stolbach L., Byrne M., Cummings F. J., McDonough E., Calabresi P. Cell-mediated and serum blocking reactivity to tumor antigens in patients with malignant melanoma. Int J Cancer. 1973 Mar 15;11(2):245–260. doi: 10.1002/ijc.2910110202. [DOI] [PubMed] [Google Scholar]
  10. Hersh E. M., Wong V. G., Freireich E. J. Inhibition of the local inflammatory response in man by antimetabolites. Blood. 1966 Jan;27(1):38–48. [PubMed] [Google Scholar]
  11. Kolb H. J., Storb R., Weiden P. L., Ochs H. D., Kolb H., Graham T. C., Floersheim G. L., Thomas E. D. Immunologic, toxicologic and marrow transplantation studies in dogs given dimethyl myleran. Biomedicine. 1974 Sep;20(5):341–351. [PubMed] [Google Scholar]
  12. Lavrin D. H., Rosenberg S. A., Connor R. J., Terry W. D. Immunoprophylaxis of methylcholanthrene-induced tumors in mice with Bacillus Calmette-Guérin and methanol-extracted residue. Cancer Res. 1973 Mar;33(3):472–477. [PubMed] [Google Scholar]
  13. Lehane D. E., Hurd E., Lane M. The effects of bleomycin on immunocompetence in man. Cancer Res. 1975 Oct;35(10):2724–2728. [PubMed] [Google Scholar]
  14. Levy N. L., Mahaley M. S., Jr, Day E. D. Serum-mediated blocking of cell-mediated anti-tumor immunity in a melanoma patient: association with BCG immunotherapy and clinical deterioration. Int J Cancer. 1972 Sep 15;10(2):244–248. doi: 10.1002/ijc.2910100203. [DOI] [PubMed] [Google Scholar]
  15. Makinodan T., Santos G. W., Quinn R. P. Immunosuppressive drugs. Pharmacol Rev. 1970 Jun;22(2):189–247. [PubMed] [Google Scholar]
  16. Mathé G., Kamel M., Dezfulian M., Halle-Pannenko O., Bourut C. An experimental screening for "systemic adjuvants of immunity" applicable in cancer immunotherapy. Cancer Res. 1973 Sep;33(9):1987–1997. [PubMed] [Google Scholar]
  17. Mavligit G., Gutterman J. U., McBride C., Hersh E. M. Tumor-directed immune reactivity and immunotherapy in malignant melanoma. Current status. Prog Exp Tumor Res. 1974;19:222–252. doi: 10.1159/000395859. [DOI] [PubMed] [Google Scholar]
  18. Mihich E. Combined effects of chemotherapy and immunity against leukemia L1210 in DBA-2 mice. Cancer Res. 1969 Apr;29(4):848–854. [PubMed] [Google Scholar]
  19. Mitchell M. S., DeConti R. C. Immunosuppression by 5-fluorouracil. Cancer. 1970 Oct;26(4):884–889. doi: 10.1002/1097-0142(197010)26:4<884::aid-cncr2820260422>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  20. Mitchell M. S., Kohorn E. I. Cell-mediated immunity and blocking factor in ovarian carcinoma. Obstet Gynecol. 1976 Nov;48(5):590–597. [PubMed] [Google Scholar]
  21. Mitchell M. S., Wade M. E., DeConti R. C., Bertino J. R., Calabresi P. Immunosuppressive effects of cytosine arabinoside and methotrexate in man. Ann Intern Med. 1969 Mar;70(3):535–547. doi: 10.7326/0003-4819-70-3-535. [DOI] [PubMed] [Google Scholar]
  22. Morton D., Eilber F. R., Malmgren R. A., Wood W. C. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery. 1970 Jul;68(1):158–164. [PubMed] [Google Scholar]
  23. Ono R., Nishiwaki H., Kawashima K., Uetani T., Hirano M. Lack of immunosuppressive effect of bleomycin on the primary response of mice to sheep red blood cells. Gan. 1971 Aug;62(4):267–274. [PubMed] [Google Scholar]
  24. PREHN R. T., MAIN J. M. Immunity to methylcholanthrene-induced sarcomas. J Natl Cancer Inst. 1957 Jun;18(6):769–778. [PubMed] [Google Scholar]
  25. Perper R. J., Zee T. W., Mickelson M. M. Purification of lymphocytes and platelets by gradient centrifugation. J Lab Clin Med. 1968 Nov;72(5):842–848. [PubMed] [Google Scholar]
  26. Piessens W. F., Heimann R., Legros N., Heuson J. C. Effect of Bacillus Calmette-Guérin on mammary tumor formation and cellular immunity in dimethylbenz(a)anthracene-treated rats. Cancer Res. 1971 Aug;31(8):1061–1065. [PubMed] [Google Scholar]
  27. SANTOS G. W., OWENS A. H., Jr, SENSENBRENNER L. L. EFFECTS OF SELECTED CYTOTOXIC AGENTS ON ANTIBODY PRODUCTION IN MAN; A PRELIMARY REPORT. Ann N Y Acad Sci. 1964 Mar 31;114:404–423. doi: 10.1111/j.1749-6632.1964.tb53594.x. [DOI] [PubMed] [Google Scholar]
  28. Sjögren H. O., Hellström I., Bansal S. C., Hellström K. E. Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen--antibody complexes. Proc Natl Acad Sci U S A. 1971 Jun;68(6):1372–1375. doi: 10.1073/pnas.68.6.1372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Takasugi M., Klein E. A microassay for cell-mediated immunity. Transplantation. 1970 Mar;9(3):219–227. doi: 10.1097/00007890-197003000-00005. [DOI] [PubMed] [Google Scholar]
  30. de Vries J. E., Cornain S., Rumke P. Cytotoxity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short- and long-term cultured melanoma cells,. Int J Cancer. 1974 Oct 15;14(4):427–434. doi: 10.1002/ijc.2910140402. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES